Table 1.
FDA-approved therapeutic drugs for lung cancers
| Drug (brand name) | Sponsor | Properties | Indication | Approval date | Review |
|---|---|---|---|---|---|
|
Vinorelbine tartrate (Navelbine) |
Pierre Fabre | Microtubule-destabilizing agent | NSCLC | 12/23/1994 | P |
| Gefitinib (Iressa) | AstraZeneca | EGFR inhibitor | NSCLC | 05/05/2003 | P |
| Erlotinib HCl (Tarceva) | OSI Pharmas | EGFR inhibitor | NSCLC | 11/18/2004 | P |
| Afatinib dimaleate (Gilotrif) | Boehringer Ingelheim | EGFR, HER2, and HER4 inhibitor | Metastatic NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutation | 07/12/2013 | P, O |
| Osimertinib mesylate (Tagrisso) | AstraZeneca | EGFR inhibitor | NSCLC with EGFRT790M mutations | 11/13/2015 | P, O |
| Dacomitinib (Vizimpro) | Pfizer | EGFR inhibitor | EGFR-mutated NSCLC | 09/27/2018 | P, O |
| Necitumumab (Portrazza) | Eli Lilly | EGFR-directed mAb | NSCLC | 11/24/2015 | S, O |
| Amivantamab (Rybrevant) | Janssen Biotech | EGFR- and MET-bispecific antibody | EGFR exon 20-mutated NSCLC | 05/21/2021 | P |
| Mobocertinib succinate (Exkivity) | Takeda | EGFR inhibitor | EGFR exon 20-mutated NSCLC | 09/15/2021 | P, O |
| Crizotinib (Xalkori) | Merck & Co | Multitarget TKI (ALK, ROS1, and MET) | ALK-positive advanced or metastatic NSCLC | 08/26/2011 | P, O |
| Ceritinib (Zykadia) | Novartis | Multitarget TKI (ALK, IGF1R, INSR, and ROS1) | ALK-positive metastatic NSCLC | 04/29/2014 | P, O |
| Alectinib HCl (Alecensa) | Roche | ALK inhibitor | NSCLC | 12/11/2015 | P, O |
| Brigatinib (Alunbrig) | Takeda | Multitarget TKI (ALK, EGFR, IGF1R, FLT3, and ROS1) | ALK-positive NSCLC | 04/28/2017 | P, O |
| Lorlatinib (Lorbrena) | Pfizer | Multitarget TKI (ALK and ROS1) | ALK-positive NSCLC | 11/02/2018 | P, O |
| Capmatinib HCl (Tabrecta) | Novartis | MET inhibitor | NSCLC | 05/06/2020 | P, O |
| Tepotinib HCl (Tepmetko) | Emd Serono | MET inhibitor | NSCLC | 02/03/2021 | P, O |
| Selpercatinib (Retevmo) | Loxo Oncology | RET inhibitor | RET fusion-positive NSCLC and thyroid cancer | 05/08/2020 | P, O |
| Pralsetinib (Gavreto) | Genentech | RET inhibitor | RET fusion-positive NSCLC | 09/04/2020 | P, O |
| Entrectinib (Rozlytrek) | Genentech | Multitarget TKI (TRKs, ROS1, and ALK) | NTRK fusion-positive solid tumors and ROS1-positive NSCLC | 08/15/2019 | P, O |
| Sotorasib (Lumakras) | Amgen | KRASG12C inhibitor | KRASG12C-mutated NSCLC | 05/28/2021 | P, O |
| Topotecan HCl (Hycamtin) | Novartis | DNA topoisomerases inhibitor | Relapsed SCLC | 05/28/1996 | P |
| Lurbinectedin (Zepzelca) | Jazz | DNA alkylating drug | SCLC | 06/15/2020 | P, O |
ALK Anaplastic lymphoma kinase; EGFR Epidermal growth factor receptor; HER2/4 Human epidermal growth factor receptor 2/4; IGF1R Insulin-like growth factor-1 receptor; INSR Insulin receptor; NSCLC Non-small-cell lung cancer; NTRK Neurotrophic tyrosine receptor kinase; O Orphan; P Priority; RET Rearranged during transfection; ROS1 ROS proto-oncogene 1; S Standard; SCLC Small-cell lung cancer; TKI Tyrosine kinase inhibitor; TRKs Tropomyosin receptor kinases